Sean Grant Sells 4,949 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CFO Sean Grant sold 4,949 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the transaction, the chief financial officer directly owned 114,181 shares in the company, valued at approximately $4,793,318.38. The trade was a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Vera Therapeutics Trading Down 1.6%

Vera Therapeutics stock traded down $0.69 during midday trading on Wednesday, hitting $41.68. 776,869 shares of the stock were exchanged, compared to its average volume of 897,432. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The stock’s 50-day simple moving average is $46.63 and its 200 day simple moving average is $35.30. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $56.05. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of -10.45 and a beta of 1.16.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in shares of Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after buying an additional 236 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Vera Therapeutics during the fourth quarter worth about $46,000. Quantbot Technologies LP purchased a new position in shares of Vera Therapeutics in the second quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Vera Therapeutics in the fourth quarter valued at approximately $71,000. Finally, Virtus Investment Advisers LLC lifted its holdings in Vera Therapeutics by 14.8% during the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after buying an additional 539 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Pivotal Research set a $73.00 price objective on Vera Therapeutics in a report on Friday, December 5th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. Wedbush raised their price objective on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Finally, The Goldman Sachs Group boosted their price objective on shares of Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a report on Friday, December 19th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $77.18.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.